Thinking of joining a study?

Register your interest

Become a volunteer?

NCT05864196 | RECRUITING | Prostate Cancer

Two Fraction Prostate SBRT With DIL SIB
Sponsor:

NYU Langone Health

Brief Summary:

Phase I/Ib, single arm trial of Two-Fraction Stereotactic Body Radiation Therapy (SBRT) with an MRI directed, dominant intraprostatic lesion (DIL), simultaneous integrated boost (SIB) based on genomic classification in the treatment of localized prostate cancer. The primary purpose of this study is to determine the feasibility and safety of two fraction SBRT in patients with localized prostate cancer.

Condition or disease

Prostate Cancer

Intervention/treatment

Two-Fraction Stereotactic Body Radiation Therapy (SBRT)

Phase

PHASE1

Study Type : INTERVENTIONAL
Estimated Enrollment : 80 participants
Masking : NONE
Primary Purpose : TREATMENT
Official Title : A Phase I/Ib, Single Arm Study of Two Fraction Stereotactic Body Radiation Therapy (SBRT) With Dominant Lesion Simultaneous Integrated Boost (SIB) for the Treatment of Low to Intermediate Risk Prostate Cancer
Actual Study Start Date : 2023-07-17
Estimated Primary Completion Date : 2025-06
Estimated Study Completion Date : 2026-06

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years
Sexes Eligible for Study: MALE
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • * Patient age greater than or equal 18
  • * Localized adenocarcinoma of the prostate
  • * Biopsy-proven diagnosis of prostate adenocarcinoma
  • * Low to intermediate risk National Comprehensive Cancer Network (NCCN) disease
  • * TX-T2c-8th addition staging
  • * PSA\<20 ng/ml
  • * Grade group 3 or less
  • * Proper rectal space replacement required as determined by the treating radiation oncologist
  • * Prostate size less than 60cc defined at time of simulation based on MRI
  • * Patient ability to undergo MRI and documented dominant Prostate Imaging Reporting and Data System (PI-RADS) 3 or higher lesion
  • -- Exception is very low risk, low risk, or favorable intermediate risk with a low to intermediate decipher score in which case an SIB is not utilized
  • * Androgen-deprivation therapy (ADT) is left to the discretion of the treating radiation oncologist
  • * Agreement to use effective contraceptive methods such as condoms and spermicidal foam, intrauterine device, or for their partner to use prescription birth control pills
  • * Ability to give informed consent
Exclusion Criteria
  • * High risk disease
  • * Pelvic lymph node involvement
  • * Prophylactic lymph node irradiation requirement as determined by the treating radiation oncologist
  • * Evidence of clinical or radiological extracapsular extension or seminal vesicle invasion
  • * Prior radiation to the pelvis
  • * Prior malignancies within the last 5 years
  • * Inability to meet pre-specified 2 fraction DVH constraints
  • * Prostate size \> 60cc as measures at treatment planning MRI
  • * Active significant inflammatory bowel disease (IBD) or rheumatological disease
  • * Prior prostate surgeries
  • * Previous uro lift
  • * Transurethral resection of the prostate (TURP) within 6 months of SBRT
  • * "Reasonable" urinary, bowel, and erectile function as defined by the pre-treatment EPIC questionnaire (\>50 overall summary score for each domain)
  • * Men of reproductive potential may not participate unless they agree to use an effective contraceptive method
Two Fraction Prostate SBRT With DIL SIB

Location Details

NCT05864196

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

RECRUITING

United States, New York

NYU Langone Hospital - Long Island

Mineola, New York, United States, 11501

RECRUITING

United States, New York

NYCyberKnife at Perlmutter Cancer Center

New York, New York, United States, 10016